[Estimation of the spectrum of antihelminthic activity of VIVALIN (VIG-08)].
F S
FS
Mikhaĭlitsyn
N I
NI
Koshevarov
I A
IA
Arkhipov
A B
AB
Eleev
S N
SN
Trusov
D P
DP
Sevbo
D000284:Administration, Oral; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage* / Q000737:chemistry / Q000302:isolation & purification; D002417:Cattle; D002589:Cestoda / Q000302:isolation & purification; D004353:Drug Evaluation, Preclinical; D005210:Fasciola hepatica / Q000302:isolation & purification; D005211:Fascioliasis / Q000188:drug therapy / Q000662:veterinary; D005243:Feces / Q000469:parasitology; D005260:Female; D006373:Helminthiasis / Q000188:drug therapy* / Q000469:parasitology; D006374:Helminthiasis, Animal / Q000188:drug therapy* / Q000469:parasitology; D008989:Monieziasis / Q000188:drug therapy / Q000469:parasitology; D009348:Nematoda / Q000302:isolation & purification; D009349:Nematode Infections / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary; D010270:Parasite Egg Count; D012457:Salicylamides / Q000008:administration & dosage* / Q000737:chemistry / Q000302:isolation & purification; D012756:Sheep
D000871:Anthelmintics; C510075:N-(4-methylphenyl)-3,5-dibromosalicylamide; D012457:Salicylamides